On April 22, 2026 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, reported that its abstract has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, IL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The accepted abstract, titled "Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy," highlights preclinical research supporting Xenetic’s DNase-based therapeutic approach designed to enhance CAR T-cell activity and improve antitumor responses.

Presentation Details:

Session Title: Hematologic Malignancies – Plasma Cell Dyscrasia (Poster Session)

Abstract Title: Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy

Poster Board: 410

Presentation Date & Time: June 1, 2026, 9:00 AM – 12:00 PM CDT

Presenter: Alexey V. Stepanov, PhD

The poster will be available to conference attendees during the scheduled session. For more information, please visit asco.org.

(Press release, Xenetic Biosciences, APR 22, 2026, View Source [SID1234664693])